Precirix and IFE sign clinical trial manufacturing agreement
Precirix NV, a clinical-stage biotechnology company developing novel radiopharmaceuticals in oncology, and the Institute for Energy Technology (IFE), a manufacturer of radiopharmaceutical products based in Norway, today announced an agreement for the supply of Precirix’ radiopharmaceuticals in Europe. The agreement with IFE will provide long-term clinical trial supply of Precirix’ product candidates that combine camelid-derived single-domain antibodies with Iodine-131. Technology transfer and manufacturing setup will commence in the following weeks.
“Securing clinical supply is of significant importance to execute our ambitious clinical development plans. Precirix is currently running a Phase I/II trial and advancing its second pipeline product to the clinic.”, said Ruth Devenyns, Chief Executive Officer of Precirix, “We are excited to start working with IFE, a leader in the field of radiopharmaceutical manufacturing. With this third supplier on board, we will be able to cover North-America as well as Europe, the major regions targeted in our clinical trials.”
Erik Flatmark, Director Radiopharmacy division at IFE commented, “Precirix’ platform of iodinated sdAbs is proving to be a solid platform technology. We look forward to working with the company and contribute to bringing these innovative radiopharmaceuticals to patients.”
About Precirix NV
Precirix is a private, clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing precision radiopharmaceuticals, using camelid single-domain antibodies labeled with radioisotopes. The company has a broad pipeline with one product candidate in a Phase I/II clinical trial and two in advanced preclinical stage. Research on multiple isotopes, linker technology and combination therapies further expand the platform. Precirix’ technology also allows for a theranostic approach, where patients can be selected using a low dose/imaging version of the product, followed by a higher therapeutic dose for treatment.